Fate Therapeutics, Inc.
Investor Relations Department
3535 General Atomics Ct.
Suite 200
San Diego, CA 92121
United States

Visit IR website
Sign-up for Email alerts

NASDAQ: FATE	
Last Trade:	4.51
Trade Time:	12:31 PM ET Mar 30, 2017
Change:	-0.07 (-1.531%)
Day Range	4.46 - 4.62
52-Week Range	1.47 - 5.68
Volume	112,058

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

We are a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies. Our pipeline is comprised of cell-based therapies for cancer and immune disorders. Our cellular immunotherapies are based on our novel ex vivo cell programming approach, which we apply to modulate the therapeutic function and direct the fate of hematopoietic cells.... (more)

Stock Performance

Press Releases [View all]

Mar 16, 2017
Fate Therapeutics Reports Fourth Quarter 2016 Financial Results

Mar 13, 2017
Fate Therapeutics Announces FDA Clearance of Investigational New Drug Application for FATE-NK100 Natural Killer Cell Cancer Immunotherapy

Mar 9, 2017
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2016 Financial Results

Mar 2, 2017
Fate Therapeutics to Highlight Natural Killer Cell Programs and Engineered Pluripotent Cell Platform for Off-the-Shelf Cancer Immunotherapy at the 2017 AACR Annual Meeting

Mar 1, 2017
Fate Therapeutics to Present at Two Upcoming Conferences in March

Upcoming Events [View all]

Apr 4, 2017 8:00 AM ET
2017 AACR Annual Meeting

Financials [View all]

Mar 16, 2017
Annual Report (10-K)

Mar 22, 2017
Proxy Statement (DEF 14A)

Nov 7, 2016
Quarterly Report (10-Q)

Aug 8, 2016
Quarterly Report (10-Q)

May 9, 2016
Quarterly Report (10-Q)